Work

Abstract C75: Overcoming KRAS/LKB1 mutant NSCLC resistance to BET bromodomain inhibitors with gemcitabine or Mcl-1 inhibition

Year: 2015

Type: conference-abstract

Source: Molecular Cancer Therapeutics

DOI: 10.1158/1535-7163.targ-15-c75

Authors: Michael Kahle, Margaret Soucheray, Jeffrey Becker, Eiki Kikuchi, Inés Pulido, Esra Akbay, Camilla Christensen, Wei Qiu, Fatima Al-Shahrour, Neil Johnson, Julián Carretero, Kwok-Kin Wong, Takeshi Shimamura

Institutions: Loyola University Chicago, Dana-Farber Cancer Institute, Universitat de València, Spanish National Cancer Research Centre, Fox Chase Cancer Center

Language: English

Topic: Protein Degradation and Inhibitors

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2321640347

Cites:

Cited by:

Related to: 10